Document is current
Any future updates will be listed below
-
Authors
Cohen, David
Bewley, Anthony https://orcid.org/0000-0003-1195-0290
Wollenberg, Andreas https://orcid.org/0000-0003-0177-8722
Hong, H. Chih-ho https://orcid.org/0000-0001-9963-8319
Armstrong, April https://orcid.org/0000-0003-0064-8707
Jonsen, Emilie
Maslin, Douglas https://orcid.org/0000-0002-5440-4436
Thoning, Henrik
von Eyben, Rie
Chovatiya, Raj https://orcid.org/0000-0001-6510-399X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04871711 at ClinicalTrials.govnct04872101 at ClinicalTrials.govDocuments that mention this clinical trial
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema
https://doi.org/10.1007/s13555-025-01592-y
Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD)
https://doi.org/10.1007/s13555-024-01114-2
nct04417894 at ClinicalTrials.govDocuments that mention this clinical trial
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema
https://doi.org/10.1007/s13555-025-01592-y
Documents that mention this clinical trial
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema
https://doi.org/10.1007/s13555-025-01592-y
-
Funding
Funding for this research was provided by:
LEO Pharma
- License Information
-
More Information
Article History
Received: 24 September 2025
Accepted: 31 October 2025
First Online: 15 November 2025
Declarations
:
: David Cohen: consultant and receives honoraria from Ferndale Laboratories, Medimetriks (past), LEO Pharma, Union Chimique Belge, Novartis (past), Dualitas, FIDE and Cosmetic Ingredient Review. He reports stock or stock options for, Evommune and Timber (past). He serves on the board of directors for Timber (past) and Evommune. Anthony Bewley has received ad hoc consultancy/travel/lecturing fees from AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. Andreas Wollenberg: advisor or paid speaker for, or participated in clinical trials (with honoraria paid to the institution) sponsored by: AbbVie, Aileens, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, LEO Pharma, L’Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Roche, Sandoz, Santen, Sanofi-Aventis and UCB. H. Chih-ho Hong: advisor/lecturer/investigator for Abbvie, Amgen, Arcutis, Aslan, Bausch Health, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Evelo Biosciences, Galderma, GSK, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Roche, UCB. April Armstrong: research investigator or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO Pharma, UCB, Janssen, Lilly, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer and Modmed. Raj Chovatiya: advisor, consultant, speaker, or investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRexBio and UCB. Raj Chovatiya is an Editorial Board member of Dermatology and Therapy . Raj Chovatiya was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Emilie Jonsen, Douglas Maslin, Henrik Thoning and Rie von Eyben are employees of LEO Pharma A/S.
: All three trials had ethical approval by institutional review boards/ethics committees and were conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guideline and applicable laws and regulations. All patients provided written informed consent. Ethical approval for this analysis was not required.
